FDA approves 1st gene therapy for Wiskott-Aldrich syndrome

Ella Jeffries / beckershospitalreview - The FDA has approved Waskyra (etuvetidigene autotemcel), the first gene therapy for Wiskott-Aldrich syndrome, a rare and life-threatening immune disorder. Waskyra is indicated for pediatric patients 6 months and older, as well as adults with Wiskott-Aldri…

AI Summary: In a landmark decision, the FDA approved Waskyra – the first gene therapy for Wiskott‐Aldrich syndrome – offering new hope for patients with this rare and life‐threatening immune disorder. The agency’s flexible approach in handling rare disease treatments marks a turning point in precision medicine.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

Anastasia Conti: Excited to Speak at CRISPRMED26 in Copenhagen

5 months / oncodaily

Western genetic medicine makers turn to Chinese investigator-initiated trials

5 months / endpoints / Ryan Cross

FDA Flexibility Leads to First Approved Gene Therapy for Rare Blood & Immune System Disorder

5 months / medcitynews / Frank Vinluan

FDA approves 1st gene therapy for Wiskott-Aldrich syndrome

5 months / beckershospitalreview / Ella Jeffries

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pediatric Oncology, Health IT, Long COVID, Venture Capital and look for the RSS link.

StackHealth Time Machine

More StackHealth